Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 UBIQUITIN PROTEASOME MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SCIENTIFIC RESEARCH

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CANCER TREATMENT

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Multiple Myeloma

4.3.4.1. Market size and forecast

4.3.5. Mantle Cell Lymphoma

4.3.5.1. Market size and forecast

Chapter: 5 UBIQUITIN PROTEASOME MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Ubiquitin Proteasome Market by Application

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Ubiquitin Proteasome Market by Application

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. India market size and forecast
5.4.3.4. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Ubiquitin Proteasome Market by Application

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Latin America market size and forecast
5.5.3.2. Middle East market size and forecast
5.5.3.3. Africa market size and forecast

5.5.4. LAMEA Ubiquitin Proteasome Market by Application

Chapter: 6 COMPANY PROFILES

6.1. TAKEDA PHARMACEUTICAL COMPANY LTD

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. JOHNSON & JOHNSON

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE LTD

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. NOVELIX PHARMACEUTICALS, INC

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. GLAXOSMITHKLINE PHARMACEUTICALS LTD

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. ONYX PHARMACEUTICALS, INC

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. TEVA PHARMACEUTICAL INDUSTRIES LTD.

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. MYLAN N.V.

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. NOVARTIS INTERNATIONAL AG

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. GLENMARK PHARMACEUTICALS LTD

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments